Xenetic Biosciences (XBIO) Other financing activities (2014 - 2021)
Xenetic Biosciences' (XBIO) quarterly Other financing activities came in at $3679.0 in Q4 2021, up 206.58% on a QoQ basis from $1200.0 in Q4 2019.
Xenetic Biosciences (XBIO) Other financing activities (2014 - 2021) Analysis & Trends
Xenetic Biosciences (XBIO) has 3 years of Other financing activities data on file, last reported at $3679.0 in Q4 2021.
- Quarterly Other financing activities changed N/A year-over-year to $3679.0 in Q4 2021, while the trailing twelve-month figure through Dec 2022 was $4879.0 (down 47.98% YoY) and the FY2021 annual result came in at $3679.0, changed N/A from the prior year.
- Other financing activities grew to $3679.0 in Q4 2021, from $1200.0 in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $4500.0 in Q3 2019 to a low of $1200.0 in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Xenetic Biosciences | 7.59 Mn | 1.12 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 3,679.00 |
| Dec 31, 2021 | 3,679.00 |
| Dec 31, 2019 | 1,200.00 |
| Dec 31, 2019 | 1,200.00 |
| Sep 30, 2019 | 4,500.00 |
| Sep 30, 2019 | 4,500.00 |
| Mar 31, 2014 | 101,933.00 |
| Mar 31, 2014 | 101,933.00 |